BlueGnome Licenses Karyomapping IP in Bid to Bolster Pre-Implantation Genetic-Dx Play

Cambridge, UK-based BlueGnome made the acquisition to carve out a bigger piece of the pre-implantation, genetic-diagnostic market. The firm "aims to address diagnosis of single-gene disorders using SNP-array technology," according to its CEO.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.